more

UNITY Biotechnology (UBX)

(Delayed Data from NSDQ)

$1.48 USD

+0.01 (0.68%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $1.48 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Unity (UNX) Down on Disappointing Results From Wet AMD Study

by Zacks Equity Research Published on March 28,2023

Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD study.

All You Need to Know About UNITY Biotechnology, Inc. (UBX) Rating Upgrade to Strong Buy

by Zacks Equity Research Published on October 10,2022

UNITY Biotechnology, Inc. (UBX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

UBXPositive Net Change

Bears are Losing Control Over UNITY Biotechnology, Inc. (UBX), Here's Why It's a 'Buy' Now

by Zacks Equity Research Published on August 30,2022

UNITY Biotechnology, Inc. (UBX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

UBXPositive Net Change

Are Options Traders Betting on a Big Move in Unity Biotechnology (UBX) Stock?

by Zacks Equity Research Published on January 12,2021

Investors need to pay close attention to Unity Biotechnology (CRMD) stock based on the movements in the options market lately.

UBXPositive Net Change

medical

Unity Biotechnology (UBX) Jumps: Stock Rises 7.1%

by Zacks Equity Research Published on August 25,2020

Unity Biotechnology (UBX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

medical

Unity Shares Slump 66% As Lead Arthritis Drug Fails in Study

by Zacks Equity Research Published on August 18,2020

Unity's (UBX) lead pipeline candidate, UBX0101, fails to meet primary endpoint in a phase II study in patients with moderate-to-severe painful osteoarthritis of the knee.

biotechs

Moving Average Crossover Alert: Unity Biotechnology

by Zacks Equity Research Published on June 08,2020

Unity Biotechnology, Inc. (UBX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.